Biography

Aditya Bagrodia, M.D., is an Assistant Professor in the Department of Urology at UT Southwestern Medical Center, where he is the Dedman Family Scholar in Clinical Care. 

Dr. Bagrodia holds a bachelor of science degree from Rhodes College. While earning a medical degree with highest honors at the University of Tennessee Health Sciences Center, he was awarded a Doris Duke Clinical Research Fellowship at UT Southwestern Medical Center.

After completing his residency in urology at UT Southwestern, he received advanced training in urologic oncology through a fellowship at Memorial Sloan Kettering Cancer Center, where he was awarded a Urology Care Foundation Research Scholars Grant by the American Urological Association.

Dr. Bagrodia’s clinical practice focuses on treating all urologic malignancies, including adrenal, upper tract, renal, bladder, prostate, penile, and testicular cancers. He has expertise in complex multidisciplinary management and minimally invasive approaches to urologic surgery.

Dr. Bagrodia has conducted extensive research in urologic oncology, primarily in biomarker profiles and molecular signatures of urologic tumors as predictors of clinical outcomes. He is funded through competitive grants from the Cancer Prevention and Research Institute of Texas (CPRIT), intramural research grants, and the National Institutes of Health.

Both his clinical practice and research centers on patients with germ cell tumors (most commonly testicular cancer). His laboratory focuses on sequencing efforts to understand tumor evolution and heterogeneity in germ cell tumors and identifying novel biomarkers to recognize occult metastatic disease. The Bagrodia lab also conducts experiments in cell lines, zebrafish germ cell tumor models, and mice to understand the biologic implications of genetic alterations that are seen exclusively among patients with cisplatin-resistance disease. He is actively working on molecular biomarkers to identify minimal residual disease burden. On the clinical side, Dr. Bagrodia is actively involved in understanding and overcoming unique socioepidemiologic considerations that adversely impact oncologic outcomes in patients with germ cell tumors. He is also the principal investigator for several germ cell tumor-directed clinical trials at UT Southwestern (including NCT03426865 and NCT02537548).

Dr. Bagrodia is the principal author or co-author of more than 100 articles in peer-reviewed publications such as Journal of Clinical Oncology, Nature Genetics, European Urology, Journal of Urology, Urologic Oncology, and Urology. He is also a reviewer for many of these publications, as well as for the British Journal of Urology, Journal of Clinical Pathology, and Annals of Surgical Oncology.

In 2019, Dr. Bagrodia received UT Southwestern's Rising Star Award.

Education

Medical School
University of Tennessee Center for the Health Sciences (2009)
Residency
UT Southwestern Medical Center (2014)
Fellowship
Memorial Sloan Kettering Cancer Center (2016), Urologic Oncology

Publications

Featured Publications LegendFeatured Publications

Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.
Bagrodia A, Lee BH, Lee W, Cha EK, Sfakianos JP, Iyer G, Pietzak EJ, Gao SP, Zabor EC, Ostrovnaya I, Kaffenberger SD, Syed A, Arcila ME, Chaganti RS, Kundra R, Eng J, Hreiki J, Vacic V, Arora K, Oschwald DM, Berger MF, Bajorin DF, Bains MS, Schultz N, Reuter VE, Sheinfeld J, Bosl GJ, Al-Ahmadie HA, Solit DB, Feldman DR J. Clin. Oncol. 2016 Sep
Genomic characterization of response to chemoradiation in urothelial bladder cancer.
Desai NB, Scott SN, Zabor EC, Cha EK, Hreiki J, Sfakianos JP, Ramirez R, Bagrodia A, Rosenberg JE, Bajorin DF, Berger MF, Bochner BH, Zelefsky MJ, Kollmeier MA, Ostrovnaya I, Al-Ahmadie HA, Solit DB, Iyer G Cancer 2016 Aug
Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma.
Bagrodia A, Cha EK, Sfakianos JP, Zabor EC, Bochner BH, Al-Ahmadie HA, Solit DB, Coleman JA J. Urol. 2016 Jun 195 6 1684-9
Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma.
Bagrodia A, Krabbe LM, Gayed BA, Kapur P, Bernstein I, Xie XJ, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclerq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Margulis V Urology 2014 Nov 84 5 1134-40
Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
Lotan Y, Bagrodia A, Passoni N, Rachakonda V, Kapur P, Arriaga Y, Bolenz C, Margulis V, Raj GV, Sagalowsky AI, Shariat SF Eur. Urol. 2013 Sep 64 3 465-71
Prospective evaluation of molecular markers for the staging and prognosis of upper tract urothelial carcinoma.
Bagrodia A, Youssef RF, Kapur P, Darwish OM, Cannon C, Belsante MJ, Gerecci D, Sagalowsky AI, Shariat SF, Lotan Y, Margulis V Eur. Urol. 2012 Jul 62 1 e27-9

Honors & Awards

  • Rising Star Award - UT Southwestern
    (2019)